$VRTX has released its Q4 2024 earnings report, highlighting a revenue of $2.91B (+15.66% YoY) but an EPS of $3.98, missing estimates by $0.04. Key risks include rising expenses and potential IP issues outside the U.S. As for growth, Vertex is driving expansion with the launch of JOURNA VX and ALYFTREK, paving pathways for increased patient access. Future opportunities focus on penetrating the pain market and global CF therapies, yet competition remains. 📊💡 For more details, check valueverge.com/VRTX.